These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 11235214

  • 21. Clinical relevance of transurethral resection of the prostate in "asymptomatic" patients with an elevated prostate-specific antigen level.
    van Renterghem K, Van Koeveringe G, Achten R, Van Kerrebroeck P.
    Eur Urol; 2007 Sep; 52(3):819-26. PubMed ID: 17418482
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Altered prostate specific antigen reference range after transurethral resection of the prostate.
    Wolff JM, Boekels O, Borchers H, Jakse G, Rohde D.
    Anticancer Res; 2000 Sep; 20(6D):4977-80. PubMed ID: 11326651
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
    Xiao LP, Bi XJ, Li YN, Chen XQ, Zhang XF, Yu XP, Liu G, Yang MC, Song Z.
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
    [Abstract] [Full Text] [Related]

  • 30. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ, Kranse R, de Koning HJ, Schröder FH.
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [Abstract] [Full Text] [Related]

  • 31. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG.
    Br J Cancer; 2002 Sep 23; 87(7):726-8. PubMed ID: 12232754
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Intraepithelial prostatic neoplasia].
    Stepanov VN, Frank GA, Dzhioev RR.
    Urol Nefrol (Mosk); 1999 Sep 23; (1):16-9. PubMed ID: 11149338
    [Abstract] [Full Text] [Related]

  • 34. [Clinical evaluation of tandem PSA for the diagnosis and follow-up of prostate cancer].
    Okaneya T, Mizusawa H, Taguchi I, Yoneyama T.
    Hinyokika Kiyo; 1996 Nov 23; 42(11):861-7. PubMed ID: 8973936
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. TP53 mutation in prostate needle biopsies--comparison with patients follow-up.
    Ecke TH, Schlechte HH, Hübsch A, Lenk SV, Schiemenz K, Rudolph BD, Miller K.
    Anticancer Res; 2007 Nov 23; 27(6B):4143-8. PubMed ID: 18225585
    [Abstract] [Full Text] [Related]

  • 39. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
    Tsuchiya N, Ohyama C, Habuchi T.
    Gan To Kagaku Ryoho; 2005 Feb 23; 32(2):275-80. PubMed ID: 15751649
    [Abstract] [Full Text] [Related]

  • 40. [Impact of prostatic benign hyperplasia and prostatic inflammation on the increase of prostate specific antigen levels].
    Ferrero Doria R, Pérez Flores D, Terrer Artes C, Guzmán Martínez-Valls PL, Morga Egea JP, Tomás Ros M, Rico Galiano JL, Sempere Gutiérrez A, Fontana Compiano LO.
    Actas Urol Esp; 1997 Feb 23; 21(2):100-4. PubMed ID: 9214204
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.